Pharmaceutical

BlossomHill secures $100m for cancer discovery programmes 

BlossomHill has secured $100m in a Series B financing round to advance its programmes targeting cancer and autoimmune diseases.

Mar 1, 2024 - 18:00
BlossomHill secures $100m for cancer discovery programmes 
BlossomHill has secured $100m in a Series B financing round to advance its programmes targeting cancer and autoimmune diseases.
Read the original article

Tags:

Previous Article

FDA lifts two-year clinical hold on CytoDyn’s HIV trial

Next Article

1910 Genetics and Microsoft partner to enhance pharmaceutical R&D

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Medicare Advantage enrollment races past 33 million

STAT+: Medicare Advantage enrollment races past 33 million

Feb 17, 2024

Roche records 4% decline in H1 2024 net income

Roche records 4% decline in H1 2024 net income

Jul 28, 2024

SyntheticGestalt and Enamine partner on AI drug discovery models

SyntheticGestalt and Enamine partner on AI drug discove...

Jan 13, 2024